secwatch.observer — SEC 8-K summary
======================================

Issuer:     Semnur Pharmaceuticals, Inc. (SMNR)
CIK:        0001913577
Form:       8-K
Filed at:   2022-04-12T23:59:59+00:00
Accession:  0001575872-22-000269
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 5.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali Capital Acquisition Corp. prices $75M IPO, upsized to $82.5M including over-allotment
--------------------------------------------------------------------------------

- IPO of 7,500,000 units at $10.00/unit, plus over-allotment of 750,000 units, for total 8,250,000 units.
- Gross proceeds $82.5M from IPO and $5.1M from private placement of 510,000 units to sponsor.
- Trust account funded with $84.15M; proceeds held until business combination or redemption.
- Appoints Huifeng Chang, Jim Mao, Kevin D. Vassily as independent directors; board classified three classes.
- Units (DECAU), Class A shares (DECA), and warrants (DECAW) listed on Nasdaq.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1913577/000157587222000269/0001575872-22-000269-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1913577/000157587222000269/deca-20220406.htm
  HTML page:      https://secwatch.observer/filing/0001575872-22-000269

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer